Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation

Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965.

Abstract

This review will provide an overview of the principles of pharmacogenomics from basic discovery to implementation, encompassing application of tools of contemporary genome science to the field (including areas of apparent divergence from disease-based genomics), a summary of lessons learned from the extensively studied drugs clopidogrel and warfarin, the current status of implementing pharmacogenetic testing in practice, the role of genomics and related tools in the drug development process, and a summary of future opportunities and challenges.

Keywords: clopidogrel; genomics; pharmacogenetics; pharmacokinetics; warfarin.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Biological Variation, Individual
  • Biotransformation / genetics
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / pharmacokinetics*
  • Cardiovascular Agents / therapeutic use
  • Drug Development
  • Drug-Related Side Effects and Adverse Reactions / ethnology
  • Drug-Related Side Effects and Adverse Reactions / genetics
  • Drug-Related Side Effects and Adverse Reactions / prevention & control
  • Forecasting
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Genetic Variation
  • Genomics*
  • Genotyping Techniques
  • Human Genome Project
  • Humans
  • Pharmacogenetics*
  • Precision Medicine / methods*
  • Randomized Controlled Trials as Topic / methods
  • Risk Assessment
  • Sample Size

Substances

  • Cardiovascular Agents